## Ilona Kryczek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3894396/publications.pdf Version: 2024-02-01



LIONA KOVCZEK

#	Article	IF	CITATIONS
1	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
2	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019, 569, 270-274.	27.8	1,528
3	Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell, 2017, 170, 548-563.e16.	28.9	1,377
4	Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature, 2015, 527, 249-253.	27.8	897
5	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 2009, 114, 1141-1149.	1.4	688
6	B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine, 2006, 203, 871-881.	8.5	638
7	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer Discovery, 2019, 9, 1673-1685.	9.4	566
8	Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology, 2014, 147, 1393-1404.	1.3	529
9	Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nature Immunology, 2017, 18, 1332-1341.	14.5	508
10	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nature Medicine, 2021, 27, 152-164.	30.7	451
11	Induction of IL-17+ T Cell Trafficking and Development by IFN-Î <sup>3</sup> : Mechanism and Pathological Relevance in Psoriasis. Journal of Immunology, 2008, 181, 4733-4741.	0.8	433
12	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	8.2	423
13	Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment. Journal of Immunology, 2007, 178, 6730-6733.	0.8	375
14	Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2. Immunity, 2013, 39, 611-621.	14.3	366
15	Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood, 2009, 114, 357-359.	1.4	354
16	Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell, 2016, 165, 1092-1105.	28.9	340
17	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nature Immunology, 2016, 17, 95-103.	14.5	310
18	IL-22+CD4+ T Cells Promote Colorectal Cancer Stemness via STAT3 Transcription Factor Activation and Induction of the Methyltransferase DOT1L. Immunity, 2014, 40, 772-784.	14.3	309

ILONA KRYCZEK

#	Article	IF	CITATIONS
19	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. Cancer Research, 2007, 67, 8900-8905.	0.9	294
20	Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American Journal of Physiology - Cell Physiology, 2007, 292, C987-C995.	4.6	290
21	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature, 2020, 585, 277-282.	27.8	280
22	Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer. Cancer Research, 2004, 64, 5535-5538.	0.9	270
23	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metabolism, 2018, 28, 87-103.e6.	16.2	263
24	Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells. Journal of Immunology, 2006, 177, 40-44.	0.8	252
25	CD8+ TÂcells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell, 2022, 40, 365-378.e6.	16.8	250
26	Human T <sub>H</sub> 17 Cells Are Long-Lived Effector Memory Cells. Science Translational Medicine, 2011, 3, 104ra100.	12.4	236
27	Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. International Journal of Cancer, 2012, 130, 29-39.	5.1	230
28	IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer. Journal of Immunology, 2011, 186, 4388-4395.	0.8	224
29	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Research, 2016, 76, 3156-3165.	0.9	224
30	PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer. Cancer Research, 2016, 76, 275-282.	0.9	204
31	Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential. American Journal of Reproductive Immunology, 2005, 54, 369-377.	1.2	197
32	FOXP3 Defines Regulatory T Cells in Human Tumor and Autoimmune Disease. Cancer Research, 2009, 69, 3995-4000.	0.9	177
33	Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Research, 2019, 79, 3940-3951.	0.9	154
34	IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Research, 2017, 77, 2735-2745.	0.9	144
35	Interleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis. Cancer Research, 2012, 72, 420-429.	0.9	129
36	Myeloid cells in hepatocellular carcinoma. Hepatology, 2015, 62, 1304-1312.	7.3	123

Ilona Kryczek

#	Article	IF	CITATIONS
37	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. Journal of Clinical Investigation, 2020, 130, 2712-2726.	8.2	112
38	LIMIT is an immunogenic IncRNA in cancer immunity and immunotherapy. Nature Cell Biology, 2021, 23, 526-537.	10.3	96
39	Cutting Edge: IFN-Î <sup>3</sup> Enables APC to Promote Memory Th17 and Abate Th1 Cell Development. Journal of Immunology, 2008, 181, 5842-5846.	0.8	83
40	Suppression of FIP200 and autophagy by tumor-derived lactate promotes naÃ <sup>-</sup> ve T cell apoptosis and affects tumor immunity. Science Immunology, 2017, 2, .	11.9	83
41	Spatial and phenotypic immune profiling of metastatic colon cancer. JCl Insight, 2018, 3, .	5.0	73
42	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. Cancer Cell, 2021, 39, 480-493.e6.	16.8	71
43	Autophagic adaptation to oxidative stress alters peritoneal residential macrophage survival and ovarian cancer metastasis. JCI Insight, 2020, 5, .	5.0	59
44	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 978-993.	13.2	52
45	The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nature Immunology, 2021, 22, 460-470.	14.5	50
46	Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Reports, 2022, 39, 110609.	6.4	46
47	Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation. Cancer Discovery, 2021, 11, 1826-1843.	9.4	42
48	miR-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer. Cancer Research, 2018, 78, 1751-1765.	0.9	30
49	Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling. Oncolmmunology, 2016, 5, e1082704.	4.6	29
50	Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma. Oncolmmunology, 2016, 5, e1105430.	4.6	27
51	Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. Journal of Immunology, 2018, 201, 814-820.	0.8	18
52	Response: Endogenous IL-17, tumor growth, and metastasis. Blood, 2010, 115, 2556-2557.	1.4	15
53	Phenotype and tissue distribution of CD28H+ immune cell subsets. Oncolmmunology, 2017, 6, e1362529.	4.6	13
54	IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer. Clinical Cancer Research, 2021, 27, 3661-3673.	7.0	6

#	Article	IF	CITATIONS
55	DOT1L affects colorectal carcinogenesis via altering T cell subsets and oncogenic pathway. Oncolmmunology, 2022, 11, 2052640.	4.6	4